Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)

Journal of Peptide Science

Volumn 21, Issue 8, 2015, Pages 651-660

  Maaß, Franziska ^a   Wüstehube Lausch, Joycelyn ^b   Dickgießer, Stephan ^a   Valldorf, Bernhard ^a   Reinwarth, Michael ^a   Schmoldt, Hans Ulrich ^b   Daneschdar, Matin ^b   Avrutina, Olga ^a   Sahin, Ugur ^b   Kolmar, Harald ^a  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b BIONTECH AG   (Germany)

Author keywords

avidity; combinatorial screening; CTLA 4; cystine knot peptides; peptide oligomerization

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENT COMPONENT C4B BINDING PROTEIN; CYSTINE KNOT PEPTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN FC FRAGMENT; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; AVIDIN; CTLA4 PROTEIN, HUMAN; CYCLOTIDE; NEUTRAVIDIN; PEPTIDE LIBRARY; PROTEIN BINDING; RECOMBINANT PROTEIN; TRYPSIN INHIBITOR MCOTI-II;

APPARENT DISSOCIATION CONSTANT; ARTICLE; BINDING AFFINITY; CELL ENGINEERING; CONTROLLED STUDY; CYSTINE KNOT MOTIF; CYTOTOXIC T LYMPHOCYTE; DISSOCIATION CONSTANT; EXPRESSION VECTOR; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METASTATIC MELANOMA; MOMORDICA COCHINCHINENSIS; PEPTIDE SYNTHESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUCROSE DENSITY GRADIENT CENTRIFUGATION; T LYMPHOCYTE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; PEPTIDE LIBRARY; PROTEIN ENGINEERING;

MOMORDICA COCHINCHINENSIS;

AVIDIN; CTLA-4 ANTIGEN; CYCLOTIDES; HUMANS; MODELS, MOLECULAR; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 84937519173     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2782     Document Type: Article

References (82)

1. Kolmar H,. Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins. Curr. Opin. Pharmacol. 2009; 9: 608-614.
2. Craik DJ, Daly NL, Waine C,. The cystine knot motif in toxins and implications for drug design. Toxicon 2001; 39: 43-60.
3. Kolmar H,. Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins. FEBS J. 2008; 275: 2684-2690.
4. Heitz A, Avrutina O, Le-Nguyen D, Diederichsen U, Hernandez JF, Gracy J, Kolmar H, Chiche L,. Knottin cyclization: impact on structure and dynamics. BMC Struct. Biol. 2008; 8: 54.
5. Reinwarth M, Nasu D, Kolmar H, Avrutina O,. Chemical synthesis, backbone cyclization and oxidative folding of cystine-knot peptides: promising scaffolds for applications in drug design. Molecules 2012; 17: 12533-12552.
6. Lahti JL, Silverman AP, Cochran JR,. Interrogating and predicting tolerated sequence diversity in protein folds: application to E. elaterium trypsin inhibitor-II cystine-knot miniprotein. PLoS Comput. Biol. 2009; 5: e1000499.
7. Kimura RH, Jones DS, Jiang L, Miao Z, Cheng Z, Cochran JR,. Functional mutation of multiple solvent-exposed loops in the Ecballium elaterium trypsin inhibitor-II cystine knot miniprotein. PLoS One 2011; 6: e16112.
8. Werle M, Kafedjiiski K, Kolmar H, Bernkop-Schnurch A,. Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration. Int. J. Pharm. 2007; 332: 72-79.
9. Werle M, Schmitz T, Huang HL, Wentzel A, Kolmar H, Bernkop-Schnurch A,. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J. Drug Target. 2006; 14: 137-146.
10. Kolmar H,. Natural and engineered cystine knot miniproteins for diagnostic and therapeutic applications. Curr. Pharm. Des. 2011; 17: 4329-4336.
11. Moore SJ, Cochran JR,. Engineering knottins as novel binding agents. Methods Enzymol. 2012; 503: 223-251.
12. Poth AG, Chan LY, Craik DJ,. Cyclotides as grafting frameworks for protein engineering and drug design applications. Biopolymers 2013; 100: 480-491.
13. Glotzbach B, Reinwarth M, Weber N, Fabritz S, Tomaszowski M, Fittler H, Christmann A, Avrutina O, Kolmar H,. Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1. PLoS One 2013; 8: e76956.
14. Getz JA, Cheneval O, Craik DJ, Daugherty PS,. Design of a cyclotide antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration. ACS Chem. Biol. 2013; 8: 1147-1154.
15. Kimura RH, Cheng Z, Gambhir SS, Cochran JR,. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res. 2009; 69: 2435-2442.
16. Liu S, Liu H, Ren G, Kimura RH, Cochran JR, Cheng Z,. PET Imaging of integrin positive tumors using F labeled knottin peptides. Theranostics. 2011; 1: 403-412.
17. Moore SJ, Hayden Gephart MG, Bergen JM, Su YS, Rayburn H, Scott MP, Cochran JR,. Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma. Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 14598-14603.
18. Moore SJ, Leung CL, Norton HK, Cochran JR,. Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging. PLoS One 2013; 8: e60498.
19. Felizmenio-Quimio ME, Daly NL, Craik DJ,. Circular proteins in plants: solution structure of a novel macrocyclic trypsin inhibitor from Momordica cochinchinensis. J. Biol. Chem. 2001; 276: 22875-22882.
20. Ji Y, Majumder S, Millard M, Borra R, Bi T, Elnagar AY, Neamati N, Shekhtman A, Camarero JA,. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J. Am. Chem. Soc. 2013; 135: 11623-11633.
21. Klotz U,. Ziconotide-a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain-a short review. Int. J. Clin. Pharmacol. Ther. 2006; 44: 478-483.
22. D'Souza C, Henriques ST, Wang CK, Craik DJ,. Structural parameters modulating the cellular uptake of disulfide-rich cyclic cell-penetrating peptides: MCoTI-II and SFTI-1. Eur. J. Med. Chem. 2014; 88: 10-18.
23. Huang YH, Chaousis S, Cheneval O, Craik DJ, Henriques ST,. Optimization of the cyclotide framework to improve cell penetration properties. Front. Pharmacol. 2015; 6: 17.
24. Wong CT, Rowlands DK, Wong CH, Lo TW, Nguyen GK, Li HY, Tam JP,. Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew. Chem. Int. Ed. Engl. 2012; 51: 5620-5624.
25. Chittasupho C,. Multivalent ligand: design principle for targeted therapeutic delivery approach. Ther. Deliv. 2012; 3: 1171-1187.
26. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ,. Hitting multiple targets with multimeric ligands. Expert Opin. Ther. Targets 2004; 8: 565-586.
27. Dervillez X, Huther A, Schuhmacher J, Griesinger C, Cohen JH, von Laer D, Dietrich U,. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. ChemMedChem 2006; 1: 330-339.
28. Lassabe G, Rossotti M, Gonzalez-Techera A, Gonzalez-Sapienza G,. Shiga-like toxin B subunit of Escherichia coli as scaffold for high-avidity display of anti-immunocomplex peptides. Anal. Chem. 2014; 86: 5541-5546.
29. McNerny DQ, Kukowska-Latallo JF, Mullen DG, Wallace JM, Desai AM, Shukla R, Huang B, Banaszak Holl MM, Baker JR, Jr,. RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. Bioconjug. Chem. 2009; 20: 1853-1859.
30. Shimamoto G, Gegg C, Boone T, Queva C,. Peptibodies: a flexible alternative format to antibodies. MAbs. 2012; 4: 586-591.
31. Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H,. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. FEBS J. 2007; 274: 86-95.
32. Chmielowski B,. Ipilimumab: a first-in-class T-cell potentiator for metastatic melanoma. J. Skin Cancer 2013; 2013: 423829.
33. Hodi FS,. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 2007; 13: 5238-5242.
34. Krummel MF, Allison JP,. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995; 182: 459-465.
35. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA,. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992; 257: 789-792.
36. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA,. Immunosuppression in vivo by a soluble form of the CTLA-4T cell activation molecule. Science 1992; 257: 792-795.
37. Leach DR, Krummel MF, Allison JP,. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
38. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012; 12: 252-264.
39. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA,. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 8372-8377.
40. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, Baker B, Zhu B, Le Gall S, Waring MT, Ahern R, Moss K, Kelleher AD, Coffin JM, Freeman GJ, Rosenberg ES, Walker BD,. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 2007; 8: 1246-1254.
41. Ruderman EM, Pope RM,. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 2005; 7 (Suppl 2): S21-25.
42. Zubairi S, Sanos SL, Hill S, Kaye PM,. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur. J. Immunol. 2004; 34: 1433-1440.
43. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P,. Ipilimumab. Nat. Rev. Drug Discov. 2011; 10: 411-412.
44. Heitz A, Hernandez JF, Gagnon J, Hong TT, Pham TT, Nguyen TM, Le-Nguyen D, Chiche L,. Solution structure of the squash trypsin inhibitor MCoTI-II. A new family for cyclic knottins. Biochemistry 2001; 40: 7973-7983.
45. Hernandez JF, Gagnon J, Chiche L, Nguyen TM, Andrieu JP, Heitz A, Trinh Hong T, Pham TT, Le Nguyen D,. Squash trypsin inhibitors from Momordica cochinchinensis exhibit an atypical macrocyclic structure. Biochemistry 2000; 39: 5722-5730.
46. Van den Brulle J, Fischer M, Langmann T, Horn G, Waldmann T, Arnold S, Fuhrmann M, Schatz O, O'Connell T, O'Connell D, Auckenthaler A, Schwer H,. A novel solid phase technology for high-throughput gene synthesis. Biotechniques 2008; 45: 340-343.
47. Boder ET, Wittrup KD,. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 1997; 15: 553-557.
48. Benatuil L, Perez JM, Belk J, Hsieh CM,. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng. Des. Sel. 2010; 23: 155-159.
49. Schmoldt HU, Daneschdar M, Kolmar H, Blind M,. Microbodies. Methods Mol. Biol. 2009; 535: 361-372.
50. Angelini A, Diderich P, Morales-Sanfrutos J, Thurnheer S, Hacker D, Menin L, Heinis C,. Chemical macrocyclization of peptides fused to antibody Fc fragments. Bioconjug. Chem. 2012; 23: 1856-1863.
51. Hofmeyer T, Schmelz S, Degiacomi MT, Dal Peraro M, Daneschdar M, Scrima A, van den Heuvel J, Heinz DW, Kolmar H,. Arranged sevenfold: structural insights into the C-terminal oligomerization domain of human C4b-binding protein. J. Mol. Biol. 2013; 425: 1302-1317.
52. Reinwarth M, Glotzbach B, Tomaszowski M, Fabritz S, Avrutina O, Kolmar H,. Oxidative folding of peptides with cystine-knot architectures: kinetic studies and optimization of folding conditions. Chembiochem 2013; 14: 137-146.
53. Feige MJ, Hendershot LM,. Disulfide bonds in ER protein folding and homeostasis. Curr. Opin. Cell Biol. 2011; 23: 167-175.
54. Silverman AP, Levin AM, Lahti JL, Cochran JR,. Engineered cystine-knot peptides that bind avb3 integrin with antibody-like affinities. J. Mol. Biol. 2009; 385: 1064-1075.
55. Northfield SE, Wang CK, Schroeder CI, Durek T, Kan MW, Swedberg JE, Craik DJ,. Disulfide-rich macrocyclic peptides as templates in drug design. Eur. J. Med. Chem. 2014; 77: 248-257.
56. Getz JA, Rice JJ, Daugherty PS,. Protease-resistant peptide ligands from a knottin scaffold library. ACS Chem. Biol. 2011; 6: 837-844.
57. Zoller F, Markert A, Barthe P, Zhao W, Weichert W, Askoxylakis V, Altmann A, Mier W, Haberkorn U,. Combination of phage display and molecular grafting generates highly specific tumor-targeting miniproteins. Angew. Chem. Int. Ed. Engl. 2012; 51: 13136-13139.
58. Aboye TL, Ha H, Majumder S, Christ F, Debyser Z, Shekhtman A, Neamati N, Camarero JA,. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J. Med. Chem. 2012; 55: 10729-10734.
59. Austin J, Wang W, Puttamadappa S, Shekhtman A, Camarero JA,. Biosynthesis and biological screening of a genetically encoded library based on the cyclotide MCoTI-I. Chembiochem 2009; 10: 2663-2670.
60. Chan LY, Gunasekera S, Henriques ST, Worth NF, Le SJ, Clark RJ, Campbell JH, Craik DJ, Daly NL,. Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds. Blood 2011; 118: 6709-6717.
61. Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H,. Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase b. J. Mol. Biol. 2010; 395: 167-175.
62. Labrou NE,. Random mutagenesis methods for in vitro directed enzyme evolution. Curr. Protein Pept. Sci. 2010; 11: 91-100.
63. Tee KL, Wong TS,. Polishing the craft of genetic diversity creation in directed evolution. Biotechnol. Adv. 2013; 31: 1707-1721.
64. Sheedy C, MacKenzie CR, Hall JC,. Isolation and affinity maturation of hapten-specific antibodies. Biotechnol. Adv. 2007; 25: 333-352.
65. Darlington PJ, Kirchhof MG, Criado G, Sondhi J, Madrenas J,. Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation. J. Immunol. 2005; 175: 996-1004.
66. Cloutier SM, Couty S, Terskikh A, Marguerat L, Crivelli V, Pugnieres M, Mani JC, Leisinger HJ, Mach JP, Deperthes D,. Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol. Immunol. 2000; 37: 1067-1077.
67. Kipriyanov SM, Little M, Kropshofer H, Breitling F, Gotter S, Dubel S,. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. Protein Eng. 1996; 9: 203-211.
68. Leisner C, Loeth N, Lamberth K, Justesen S, Sylvester-Hvid C, Schmidt EG, Claesson M, Buus S, Stryhn A,. One-pot, mix-and-read peptide-MHC tetramers. PLoS One 2008; 3: e1678.
69. Shrivastava A, von Wronski M, Tweedle MF, Nunn AD,. Identification of ideal peptides for heterovalent ligands. Methods Mol. Biol. 2014; 1088: 97-105.
70. Shrivastava A, von Wronski MA, Sato AK, Dransfield DT, Sexton D, Bogdan N, Pillai R, Nanjappan P, Song B, Marinelli E, DeOliveira D, Luneau C, Devlin M, Muruganandam A, Abujoub A, Connelly G, Wu QL, Conley G, Chang Q, Tweedle MF, Ladner RC, Swenson RE, Nunn AD,. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng. Des. Sel. 2005; 18: 417-424.
71. Cannon JP, O'Driscoll M, Litman GW,. Construction, expression, and purification of chimeric protein reagents based on immunoglobulin Fc regions. Methods Mol. Biol. 2011; 748: 51-67.
72. Jazayeri JA, Carroll GJ,. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 2008; 22: 11-26.
73. Ronnmark J, Hansson M, Nguyen T, Uhlen M, Robert A, Stahl S, Nygren PA,. Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. J. Immunol. Methods 2002; 261: 199-211.
74. Kessel C, Kreuz W, Klich K, Becker-Peters K, Vorpahl F, Dietrich U, Klingebiel T, Konigs C,. Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies. ChemMedChem 2009; 4: 1364-1370.
75. Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, Padilla DP, Phillips B, Carter MB, Willman CL, Brinker CJ, Caldeira Jdo C, Chackerian B, Wharton W, Peabody DS,. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 2011; 5: 5729-5745.
76. Rademacher C, Guiard J, Kitov PI, Fiege B, Dalton KP, Parra F, Bundle DR, Peters T,. Targeting norovirus infection-multivalent entry inhibitor design based on NMR experiments. Chemistry 2011; 17: 7442-7453.
77. Brambell FW, Halliday R, Morris IG,. Interference by human and bovine serum and serum protein fractions with the absorption of antibodies by suckling rats and mice. Proc. R. Soc. Lond. B Biol. Sci. 1958; 149: 1-11.
78. Mould DR, Sweeney KR,. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr. Opin. Drug Discov. Dev. 2007; 10: 84-96.
79. Deisenhofer J,. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8Å resolution. Biochemistry 1981; 20: 2361-2370.
80. Miller S,. Protein-protein recognition and the association of immunoglobulin constant domains. J. Mol. Biol. 1990; 216: 965-973.
81. Wentzel A, Christmann A, Kratzner R, Kolmar H,. Sequence requirements of the GPNG b-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening. J. Biol. Chem. 1999; 274: 21037-21043.
82. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA,. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013; 210: 1695-1710.